Sagimet Biosciences Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sagimet Biosciences Inc. - overview
Established
2006
Location
San Mateo, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2006, Sagimet Biosciences Inc. is a clinical-stage pharmaceutical company that develops novel therapeutics for the treatment of oncology like breast cancer, astrocytoma, colon cancer, and other infectious diseases such as non-alcoholic steatohepatitis (NASH). The company was founded by Lucas Pelkmans and Urs Greber. In February 2021, Sagimet Biosciences Inc.
raised USD 80 million in venture funding from Altium Capital, Kleiner Perkins, and New Enterprise Associates. The company offers TVB-2640, which targets and synthesizes fatty acid synthase (FASN). It also offers antiviral therapeutics for the respiratory syncytial virus (RSV), cytomegalovirus (CMV), and other human pathogens. Sagimet Biosciences plans to advance its lead program, explore additional indications, and file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.
Current Investors
Kleiner Perkins, New Enterprise Associates, The Column Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.sagimet.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.